CompletedPhase 3NCT00716976
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
Studying Extragonadal germ cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- David R. Freyer, DO, MSChildren's Hospital Los Angeles
- Intervention
- sodium thiosulfate(drug)
- Enrollment
- 131 enrolled
- Eligibility
- 1-18 years · All sexes
- Timeline
- 2008 – 2021
Study locations (30)
- UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Childrens Hospital Los Angeles, Los Angeles, California, United States
- Southern California Permanente Medical Group, Los Angeles, California, United States
- Children's Hospital Central California, Madera, California, United States
- Rady Children's Hospital - San Diego, San Diego, California, United States
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- Connecticut Children's Medical Center, Hartford, Connecticut, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Lee Cancer Care of Lee Memorial Health System, Fort Myers, Florida, United States
- Nemours Children's Clinic, Jacksonville, Florida, United States
- University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
- Florida Hospital Cancer Institute at Florida Hospital Orlando, Orlando, Florida, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00716976 on ClinicalTrials.govOther trials for Extragonadal germ cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06418789High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell TumorsN.N. Petrov National Medical Research Center of Oncology
- RECRUITINGPHASE3NCT03067181Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE3NCT02375204Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell TumorsAlliance for Clinical Trials in Oncology